-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NVP-2203 in Hypercholesterolemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NVP-2203 in Hypercholesterolemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NVP-2203 in Hypercholesterolemia Drug Details: NVP-2203 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BEAM-101 in Beta Thalassaemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BEAM-101 in Beta Thalassaemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BEAM-101 in Beta Thalassaemia Drug Details: BEAM-101 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NVP-1901 in Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NVP-1901 in Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NVP-1901 in DiabetesDrug Details:NVP-1901 is under development for the treatment of diabetes. It is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NVP-1705 in Idiopathic (Essential) Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NVP-1705 in Idiopathic (Essential) Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NVP-1705 in Idiopathic (Essential) HypertensionDrug Details:NVP-1705 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Everolimus in High-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Everolimus in High-Grade Glioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Everolimus in High-Grade Glioma Drug Details: Everolimus (Afinitor, Votubia, RAD001) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IDE-161 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IDE-161 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IDE-161 in Solid Tumor Drug Details: IDE-161 is under development for the treatment...
-
Product Insights
Muscle Spasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Muscle Spasm - Drugs In Development, 2023’, provides an overview of the Muscle Spasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Muscle Spasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Idiopathic (Essential) Hypertension – Drugs In Development, 2023
Global Markets Direct’s, ‘Idiopathic (Essential) Hypertension - Drugs In Development, 2023’, provides an overview of the Idiopathic (Essential) Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Idiopathic (Essential) Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...